The Center for Biosimilars® recaps the top stories for the week of March 9, 2020.
Hi, I’m Christina Mattina for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of March 9, 2020.
Number 5: The FDA released a question-and-answer guidance for the industry about the transition coming March 23 for how certain products will be approved under a biological pathway, including exceptions to the transition and how companies will receive notifications about their applications.
Number 4: The US biosimilars market is showing healthy vital signs, said Leah Christl, Amgen’s executive director for Global Regulatory and R&D policy, while reassuring an audience that her former FDA colleagues are still champions of their work.
Number 3: The combination of growing biosimilar awareness, patent expirations, and demands to lower healthcare costs will increase uptake over the next few years, setting up some pharmaceutical firms to advance while putting others at risk, according to a recent S&P Global Ratings report.
Number 2: The FDA has granted the application for Mylan’s bevacizumab biosimilar a decision date of December 27, 2020.
Number 1: Katie Verb, director of policy and research for the biopharmaceutical industry group PhRMA, discussed recent policy changes that have increased biosimilar uptake and additional measures that could lead to greater use of biosimilars and savings for CMS and patients.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.